Statins for primary prevention: Problems with cardiovascular-risk estimation?

Nature Reviews Cardiology

Volumn 10, Issue 9, 2013, Pages 547-

  Reiner, Željko ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DOSE RESPONSE; EPIDEMIOLOGY; LETTER; PRIMARY PREVENTION; PRIORITY JOURNAL; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; HUMAN; PROCEDURES; DYSLIPIDEMIA; METHODOLOGY; NOTE;

CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRIMARY PREVENTION;

EID: 84883182510     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2013.80-c2     Document Type: Letter

References (14)

1. Huang, Y.-l., Huang, Y. & Wu, Y.-x. Statins for primary prevention in individuals at low cardiovascular risk. Nat. Rev. Cardiol. http://dx.doi.org/ 10.1038/nrcardio.2013.80-c1.
2. Reiner, Z. Statins in the primary prevention of cardiovascular disease. Nat. Rev. Cardiol. http://dx.doi.org/10.1038/nrcardio.2013.80.
3. Graham, I., Cooney, M. T., Bradley, D., Dudina, A. & Reiner, Z. Dyslipidemias in the prevention of cardiovascular disease: risks and causality. Curr. Cardiol. Rep. 14, 709-720 (2012).
4. Reiner, Z. et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 32, 1769-1818 (2011).
5. Chapman, M. J. et al. for the European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur. Heart J. 332, 1345-1361 (2010).
6. Nordestgaard, B. G. et al. for the European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur. Heart J. 23, 2844-2853 (2010).
7. Zannad, F. et al. Prevention of cardiovascular disease guided by total risk estimations-challenges and opportunities for practical implementation: highlights of a CardioVascular Clinical Trialists (CVCT) Workshop of the ESC Working Group on CardioVascular Pharmacology and Drug Therapy. Eur. J. Prev. Cardiol. 19, 1454-1464 (2012).
8. Zannad, F. et al. Risk stratification in cardiovascular disease primary prevention-scoring systems, novel markers, and imaging techniques. Fundam. Clin. Pharmacol. 26, 163-174 (2012).
9. Kaptoge, S. et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375, 132-140 (2010).
10. Perk, J. et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur. Heart J. 33, 1635-1701 (2012).
11. Graham, I. et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur. Heart J. 28, 2375-2414 (2007).
12. Grundy, S. M. et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110, 227-239 (2004).
13. van Werkhoven, J. M. et al. Multislice computed tomography coronary angiography for risk stratification in patients with an intermediate pretest likelihood. Heart 95, 1607-1611 (2009).
14. Perrone-Filardi, P. et al. Cardiac computed tomography and myocardial perfusion scintigraphy for risk stratification in asymptomatic individuals without known cardiovascular disease: a position statement of the Working Group on Nuclear Cardiology and Cardiac CT of the European Society of Cardiology. Eur. Heart J. 32, 1986-1993 (2011).